Q3 FY2025 · ended Sep 30, 2025 · Revenue $0, -100.0% YoY · Filed Nov 14, 2025
Lipella Pharmaceuticals Inc. (LIPO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2025, the quarter ended Sep 30, 2025, it reported revenue of $0 and a net loss of $1.3 million. As of Sep 30, 2025 it held $1.9 million in cash and investments and $264,083 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-1.25M
+13.2% vs year-ago quarter
Operating cash flow
$-926,057
-41.8% vs year-ago quarter
Free cash flow
$-727,710
EPS
$-0.28
+78.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.62M
+282.2% vs year-ago quarter
Net cash
$1.59M
Q3 FY2025
Operating margin
-1387.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIPO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pittsburgh, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1347242
- Former names
- LIPELLA PHARMACEUTICALS INC (until Sep 11, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $86,727 | $129,390 | $173,666 | $80,380 |
| Operating income | -$1.3M | -$1.4M | -$1.3M | -$1.5M | -$1.5M |
| Net income | -$1.3M | -$1.3M | -$1.3M | -$1.4M | -$1.4M |
| Diluted EPS | -$0.28 | -$0.31 | -$0.64 | -$1.19 | -$1.29 |
| Operating cash flow | -$926,057 | -$1.4M | -$1.4M | -$990,413 | -$653,103 |
| Total assets | $2.3M | $3.7M | $4.9M | $2.7M | $2.2M |
| Total liabilities | $862,215 | $978,534 | $776,847 | $754,417 | $701,186 |
| Stockholders' equity | $1.5M | $2.7M | $4.1M | $1.9M | $1.5M |
| Cash and investments | $1.9M | $2.8M | $4.2M | $2.2M | $1.4M |
| Total debt | $264,083 | $274,539 | $23,997 | $47,605 | $70,830 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy
|
Jul 15, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Bankruptcy
|
Mar 31, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 4, 2026 | Feb 3, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 21, 2025 | Oct 20, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2025 | Oct 3, 2025 |
All 225 Lipella Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.